Facilitating Reimbursement for Intravesical Gem...

By João L. Carapinha

April 3, 2026

Reimbursement Bladder Cancer advances with the assignment of a permanent HCPCS J-code for INLEXZOâ„¢ (gemcitabine intravesical system), effective April 1, 2026. This standardized billing code simplifies reimbursement bladder cancer treatment for adu...
100% Tariffs Impacting Pharmaceutical Manufacturing and National Security
Enhancing Obesity Treatment Pricing in South Africa Through Competitive Strat...
Real-World Evidence Integration into Cancer HTA: Scotland’s Success Story
Personalised Fertility Endometriosis Care in the UK
EU-India Pharmaceutical Trade: Opportunities and Challenges in Biopharmaceuti...
Nonclinical Safety Testing with Virtual Control Groups
Advancing Health Technology Assessment MENA: Insights and Implications for th...
Advancing Participatory Arts Health in Dutch Care Systems
Tarlatamab for Small Cell Lung Cancer Treatment
FDA Approves Once-Weekly Basal Insulin Awiqli® for Type 2 Diabetes Management
Inflation Reduction Act Impact on Clinical Trial Investment Trends
EU Alzheimer Approval Challenges: Anavex Withdraws Blarcamesine Application A...